Compare Abeona Therapeutics Inc (ABEO) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Essex Property Trust, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Essex Property Trust, Inc. trades at $280.01 (market cap $18.15B). The key difference: Essex Property Trust, Inc. is far larger — about 43.1× Abeona Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ESS | |
|---|---|---|
Market Cap | $421.19M | $18.15B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $298.33 |
52-Week Low | $4.17 | $239.61 |
Enterprise Value | $276.10M | $24.75B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ESS trades at $282.11, down 0.39% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.97, missing expectations, but raised full-year guidance after strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is trending lower in 2026. Recent news includes ESS being named a top GreenTech company and signing a 500 MWh energy storage agreement with Juniper Energy.
The outlook is mixed: raised guidance and institutional buying support upside, but technical weakness and earnings miss pose near-term risks. Valuation ratios like P/E of 19.9 and P/S of 9.05 are reasonable for a REIT, yet debt levels and regional market volatility require caution. Analyst consensus is a Moderate Buy with a $305.86 price target, suggesting 8.4% potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
